Literature DB >> 32512570

Immune Modulation in Asthma: Current Concepts and Future Strategies.

Marek Lommatzsch1.   

Abstract

Asthma treatment concepts have profoundly changed over the last 20 years, from standard therapeutic regimens for all patients with asthma towards individually tailored interventions targeting treatable traits ("precision medicine"). A precise and highly effective immune modulation with minimal adverse effects plays a central role in this new concept. Recently, there have been major advances in the treatment of asthma with immune-modulatory compounds. One example is the approval of several highly potent biologics for the treatment of severe asthma. New immune-modulatory strategies are expected to enter clinical practice in the future; these innovations will be especially important for patients with treatment-resistant asthma.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Allergen immunotherapy; Asthma; Immune modulation; Oral corticosteroids

Year:  2020        PMID: 32512570      PMCID: PMC7949236          DOI: 10.1159/000506651

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  104 in total

1.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Authors:  Marcus Maurer; Karin Rosén; Hsin-Ju Hsieh; Sarbjit Saini; Clive Grattan; Ana Gimenéz-Arnau; Sunil Agarwal; Ramona Doyle; Janice Canvin; Allen Kaplan; Thomas Casale
Journal:  N Engl J Med       Date:  2013-02-24       Impact factor: 91.245

2.  Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

Authors:  Norbert Krug; Jens M Hohlfeld; Anne-Marie Kirsten; Oliver Kornmann; Kai M Beeh; Dominik Kappeler; Stephanie Korn; Stanislav Ignatenko; Wolfgang Timmer; Cordelia Rogon; Jana Zeitvogel; Nan Zhang; Joachim Bille; Ursula Homburg; Agnieszka Turowska; Claus Bachert; Thomas Werfel; Roland Buhl; Jonas Renz; Holger Garn; Harald Renz
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

Review 3.  Barrier Epithelial Cells and the Control of Type 2 Immunity.

Authors:  Hamida Hammad; Bart N Lambrecht
Journal:  Immunity       Date:  2015-07-21       Impact factor: 31.745

4.  Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists.

Authors:  William W Busse; Eric D Bateman; Arthur L Caplan; H William Kelly; Paul M O'Byrne; Klaus F Rabe; Vernon M Chinchilli
Journal:  N Engl J Med       Date:  2018-06-28       Impact factor: 91.245

5.  Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols.

Authors:  W H Inman; A M Adelstein
Journal:  Lancet       Date:  1969-08-09       Impact factor: 79.321

6.  Targeting lipid mediators in asthma: time for reappraisal.

Authors:  Zuzana Diamant; Wytze Aalders; Amit Parulekar; Leif Bjermer; Nicola A Hanania
Journal:  Curr Opin Pulm Med       Date:  2019-01       Impact factor: 3.155

7.  Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology.

Authors:  Richard Beasley; James Harper; Grace Bird; Ingrid Maijers; Mark Weatherall; Ian D Pavord
Journal:  Am J Respir Crit Care Med       Date:  2019-06-15       Impact factor: 21.405

8.  Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma.

Authors:  J Mark FitzGerald; Eugene R Bleecker; Arnaud Bourdin; William W Busse; Gary T Ferguson; Laura Brooks; Peter Barker; Ubaldo J Martin
Journal:  J Asthma Allergy       Date:  2019-12-09

9.  The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.

Authors:  Pascal Gasser; Svetlana S Tarchevskaya; Pascal Guntern; Daniel Brigger; Rahel Ruppli; Noemi Zbären; Silke Kleinboelting; Christoph Heusser; Theodore S Jardetzky; Alexander Eggel
Journal:  Nat Commun       Date:  2020-01-08       Impact factor: 14.919

10.  Against all odds: anti-IgE for intrinsic asthma?

Authors:  Marek Lommatzsch; Stephanie Korn; Roland Buhl; Johann Christian Virchow
Journal:  Thorax       Date:  2013-05-24       Impact factor: 9.139

View more
  2 in total

1.  IgE is associated with exacerbations and lung function decline in COPD.

Authors:  Marek Lommatzsch; Timotheus Speer; Christian Herr; Rudolf A Jörres; Henrik Watz; Achim Müller; Tobias Welte; Claus F Vogelmeier; Robert Bals
Journal:  Respir Res       Date:  2022-01-04

Review 2.  The Correlation of PM2.5 Exposure with Acute Attack and Steroid Sensitivity in Asthma.

Authors:  Jingjing Luo; Han Liu; Shucheng Hua; Lei Song
Journal:  Biomed Res Int       Date:  2022-08-18       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.